Interleukin-1 mediates hemodynamic dysfunction and release of eicosanoids and tumor necrosis factor during graded bacteremia

Shock

Volumn 11, Issue 6, 1999, Pages 423-428

  Santos, Mary C ^a   Woolley, Daniel S ^a   Quinn, James V ^a   Slotman, Gus J ^a,b  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSANOID; INTERLEUKIN 1; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BACTEREMIA; FEMALE; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; SWINE; THROMBOCYTE AGGREGATION;

ANIMALS; BACTEREMIA; EICOSANOIDS; FEMALE; HEMODYNAMIC PROCESSES; INTERLEUKIN-1; PLATELET AGGREGATION; RECOMBINANT PROTEINS; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033142710     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Granowitz EV, Santos AA, Poutsiaka DD, et al: Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 338: 1423-1424, 1991.
2. Sullivan JS, Kilpatrick L, Costarino AT Jr, et al: Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pedatr 120:510-515, 1992.
3. Munoz C, Carlet J, Fitting C, et al: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754, 1991.
4. Ertel W, Morrison MH, Wang P, et al: The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg 214:141-148, 1991.
5. Leon P, Redmond P, Shou J, et al: Interleukin-1 and its relationship to endotoxin tolerance. Arch Surg 127:146-151, 1992.
6. Sheppard BC, Norton JA: Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor. Surgery 109: 698-705, 1991.
7. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269: 1829-1835, 1993.
8. Bone RC: A critical evaluation of new agents for the treatment of sepsis. JAMA 266:1686-1691, 1991.
9. Alexander HR, Doherty GM, Venzon DJ, et al: Recombinant interleukin-1 receptor antagonist (IL-1ra): Effective therapy against gram-negative sepsis in rats. Surgery 112:188-194, 1992.
10. Giroir BP: Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 21:780-789, 1993.
11. Fischer CJ Jr, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12-21, 1994.
12. Fischer CJ, Dhainaut JFA, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271:1836-1843, 1994.
13. Opal SM, Fisher CJ, Dhainaut JFA, Vincent JL, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 27:115-123, 1997.
14. Okusawa S, Gelfand JA, Ikejima T, et al: Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162-1172, 1988.
15. 2 mediates hemodynamic and respiratory dysfunction in graded bacteremia. Surgery 100:214-221, 1986.
16. Holme S, Murphy S: Influence of platelet count and size on aggregation studies. J Lab Clin Med 97:623-630, 1981.
17. Gaunt SD, Baker DC, Babib SS: Platelet aggregation studies in dogs with acute Ehrlichia platys infection. Am J Vet Res 51:290-293, 1990.
18. Winer BJ: Statistical Principals in Experimental Design, 2nd ed., New York: McGraw-Hill, 1971, pp 191-218.
19. Fischer E, Marano MA, Barber AE, et al: Comparison between effects of interleukin-1a administration and sublethal endotoxemia in primates. Am J Physiol 261:R442-452, 1991.
20. Fischer E, Marano MA, Van Zeek KJ, et al: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551-1557, 1992.
21. Kruse-Elliott KT, Olson NC: CGS 8515 and indomethacin attenuate cytokine-induced cardiopulmonary dysfunction in pigs. Am J Physiol :H1076-1086, 1993.
22. Schini VB, Catovsky S, Schray-Utz B, Busse R, Vanhoutte PM: Insulin-like growth factor I inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Circ Res 74:24-32, 1994.
23. Slotman GJ: Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis. Ann Surg 226:77-84, 1997.
24. Carozzi S, Nasini MG, Schletto C, et al: Peritoneal macrophage beta-2 macroglobulin production and bacterial peritonitis in CAPD patients. ASAIO Trans 36:M369-371, 1990.
25. Conti P, Panara MR, Barbacane RC, et al: Blocking the interleukin-1 receptor inhibits leukotriene B4 and prostaglandin E2 generation in human monocyte cultures. Cellular Immunol 145:199-209, 1992.
26. Conti P, Panara MR, Barbacane RC, Bongrazio M, Dempsey RA, Reale M: Human recombinant IL-1 receptor antagonist (IL-1Ra) inhibits leukotriene B4 generation from human monocyte suspensions stimulated by lipopolysaccharide (LPS). Clin Exp Immunol 91:526-531, 1993.
27. 4-induced immunoregulation. J Immunology 139:513-517, 1987.
28. Rola-Pleszczynski M, Lemaire I: Leukotrienes augment interleukin 1 production by human monocytes. J Immunol 136:3958-3961, 1985.
29. Van Zee KJ, Coyle SM, Calvano SE, et al: Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol 154:1499-1507, 1995.